Rafael Holdings, Inc.

For the fourth quarter and full year, the company reported a narrower net loss than in the prior year, mainly from lower general and administrative expenses and a gain on settlements of payables and notes, partly offset by higher research and development spending after Cyclo was consolidated. Cash and equivalents declined over the year, and the company submitted a New Drug Application for remibetadex after its pivotal study missed the primary endpoint in the overall population.